The domestic environment is becoming more and more perfect, with 34 innovative drugs approved in the first three quarters

At present, China's pharmaceutical industry has shown three major innovative directions: innovative drugs, innovative devices and innovative treatment methods, and is growing well.
, innovative drug research and development is the focus of the capital market in the field of biomedicine.
China's innovative pharmaceutical industry has its unique advantages, population size, market demand, clinical resources, reform, talent return, technology, etc. will become a new round of growth of innovative pharmaceutical industry, for pharmaceutical innovation into a strong impetus.
years, China's achievements in the field of innovative drugs continue to break through.
In the first three quarters of this year, a total of 34 innovative drugs (excluding biosypoloric drugs) were approved for sale in China, including 12 biologics, 18 chemicals, 3 Chinese medicines and 1 vaccine (nasal-sprayed influenza detoxification live vaccine).
from the nature of enterprises, domestic innovative drugs and imported innovative drugs are equally divided, each has 17.
In addition, according to the data, of the 34 innovative drugs approved, 9 were cancer drugs, including Roche's Enmetro-Zhu monoanti, Roche's Atletico monoanti, Haussen's Amedini, North Sea Kangcheng's Nelatini, and so on.
, as China's pharmaceutical sector reform continues to advance, the release of encouraging signs of innovation, innovative drug market environment is also constantly improving.
, China's new drug research and development has entered a new stage of development.
anti-tumor drugs, anti-infective drugs, immune system drugs, cardiovascular drugs, etc. have become the focus of many innovative pharmaceutical companies in the field.
and in China's unique environment for the development of innovative drugs, in response to the call of the market, a number of domestic innovative pharmaceutical enterprises to thrive.
such as Microcore Bio is one of them, microcore Bio is understood to be one of the few innovative pharmaceutical companies in China with first-in-class research and development capabilities for new drugs.
its research and development of Siddamine is a subtype selective histone deacetylase oral inhibitor, taking Siddamine is more clinically effective, and the cost of treatment is only about one-tenth of similar products abroad.
the advent of sydamine to enable patients with external T-cell lymphoma in China to afford the associated treatment costs.
Again, Wellcome Pharmaceuticals, which has always attached great importance to pharmaceutical innovation research, will raise 540 million yuan on the GEM in the near future in order to ensure continuous innovation ability, mainly for the pharmaceutical health industrial park project, including the construction of research and development centers.
According to the introduction, the construction of the research and development center project will be conducive to adapt to the development trend of high-tech medicine, in line with the international norms of new drug research and development, the initial construction of a new mechanism and internal vitality of the enterprise innovative drug research and development system, improve the overall level and comprehensive strength of The New Drug Research of Wellcome Pharmaceuticals.
project will provide the company with a wealth of innovative drug varieties and innovative drug dosage forms, improve the company's competitiveness, and produce greater economic benefits.
From the perspective of the main body of innovative drug development, China's emerging innovative pharmaceutical companies continue to emerge and grow rapidly, around a variety of strategies for product pipeline layout, so that China's innovative drug research and development has emerged a hundred competing situation, the development of emerging pharmaceutical companies is very rapid, began to gradually approach the traditional pharmaceutical companies research and development progress and the number of new drugs.
according to the "In-depth Research and Investment Prospects Report of China's Innovative Pharmaceutical Industry 2020-2024" released by CIC Industry Research Institute, China's innovative pharmaceutical market reached US$118.2 billion in 2017 and US$128.6 billion in 2018.
2019, china's innovative drug market size is estimated to reach $137.6 billion.
In recent years, domestic innovative drugs have been vigorously developed, but there are also industry analysis, taking into account the future competitive landscape of innovative pharmaceutical industry, financing difficulties, high-quality clinical resources constraints and other factors, the advantages of head enterprises will be further highlighted.
the next two years, the heavyweight drugs are almost entirely from multinational companies and domestic innovative drug head companies.